Vidyya Medical News Servicesm
Vidyya, from the Sanskrit "vaidya," a practitioner who has come to understand the science of life.

Volume 2 Published - 14:00 UTC    08:00 EST    30-January-2001      
Issue 30 Next Update - 14:00 UTC 08:00 EST    31-January-2001      

Vidyya Home  Vidyya

Home Of Our Sponsor, Vidyya.  Vidyya. Home

Vidyya Archives  Vidyya Archives

Search Vidyya  Search Vidyya

Visit Our Library  Ex Libris

Subscribe To Our News Service  Subscriptions

All About Us  About Vidyya

Back To Vidyya Today In Vidyyasm

Vidyya Medical News Service For 30-January-2001:

The following stories appear in full on today's Vidyya Medical News Service Web site.

The FDA has approved Cancidas (caspofungin acetate) Intravenous Infusion, a new anti-fungal medication for patients who are unresponsive to or cannot tolerate standard therapies for the invasive form of aspergillosis. Cancidas is the first approved drug in a new class of anti-fungal agents called echinocandins, which are believed to work by disrupting the creation of fungal cell walls.

For more information: FDA Approves New Treatment For Invasive Fungal Infection

In other drug news, a novel substance that breaks down vascular collagen bonds in the body significantly decreased the stiffness of blood vessels in older non-human primates, according to a study conducted by National Institute on Aging (NIA) scientists and others. The finding suggests the medication could be a new treatment for high blood pressure, heart failure, and certain vascular complications of diabetes.

For more information: Drug Decreases Blood Vessel Stiffness In Older Primates

Vidyya keeps an eye on resources that will help our readers in their everyday lives. In that vein, we have discovered that the National Cancer Institute has developed a Web-based tool to help researchers, physicians, and nurses protect research participants.

For more information: NIH Course On Human Research Protections Goes Online

Alzheimer's disease affects up to 4 million Americans. If no cure is found, that number could double in 20 years as baby boomers age. On 30 January, the Alzheimer's Disease Anti-inflammatory Prevention Trial, or ADAPT, will begin to test whether anti-inflammatory pain relievers could prevent this degenerative brain disease.

For more information: Study Underway To Test Anti-Inflammatory Medicines For Prevention Of Alzheimer's Disease

Our last article tody regards another FDA approval. Smith & Nephew Orthopaedics has received Food & Drug Administration approval for Supartz, a joint fluid therapy to treat osteoarthritis. In the United States, an estimated 20 million individuals suffer from osteoarthritis (OA) so the approval of another treatment will be welcome and successful. Supartz has been used in other countries with success for some time.

For more information: New Osteoarthritis Drug Receives FDA Approval

Today's Vidyya articles are:

As always, we hope you enjoy the issue.

Vidyya. Home |  Ex Libris |  Vidyya  | 
Subscription Information |  About Vidyya |  Vidyya Archives | 

Editor: Susan K. Boyer, RN
© Vidyya. All rights reserved.